Alexion Pharma (ALXN) Tops Q3 EPS by 66c, Updates FY Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $3.24, $0.66 better than the analyst estimate of $2.58. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.42 billion.

GUIDANCE:

Alexion Pharma sees FY2020 EPS of $11.70-$12.00, versus the consensus of $11.30. Alexion Pharma sees FY2020 revenue of $5.9-5.95 billion, versus the consensus of $5.75 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Goldman Sachs sees refinery exemptions boosting DK cash flow
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short